BACH - BACH

Description:

Mid-regional pro-Adrenomedullin (MR-proADM) is a novel biomarker, which reflects vascular and endothelial status of the heart and the microcirculation. The BACH trial sought to compare the efficacy of MR-proADM and brain natriuretic peptide (BNP) and N-terminal portion of probrain natriuretic peptide (NT-proBNP) in prognosticating patients presenting with shortness of breath.